Genedata Wins 2019 Bio-IT World Best of Show Award for Deep Learning-Based Genedata Imagence

Innovative software solution revolutionizes high-content image analysis workflow using AI approach

April 25, 2019
Basel, Switzerland

Genedata, a leading provider of advanced software solutions for biopharmaceutical R&D, today announced it received the 2019 Bio-IT World Conference & Expo Best of Show Award for Genedata Imagence^® in the “No BS AI” category. Genedata Imagence is the industry’s first commercial, instrument-independent solution for automated high-content screening (HCS) image analysis at an enterprise scale, which applies a deep-learning approach.  Judged by a Bio-IT World panel of experts from academia and industry, Genedata Imagence was recognized for its innovation and ability to “measurably improve workflow or capacity, enabling better research.”

Imagence Drives Research Forward
According to Bio-IT World judges, “imaging is the perfect use case for AI and the one with the most powerful and immediate impact. This new product – Genedata Imagence – is one the judges are excited to watch closely as it empowers biologists to make full use of AI to drive research forward.”

The deep learning-based solution accelerates, by orders of magnitude, the time-consuming and complex process of analyzing phenotypic high-content images. Delivering reproducible, unbiased results proven to be equal to or better than results from more traditional analysis approaches, Genedata Imagence enables biologists to quickly and routinely set up and analyze HCS campaigns without image analysis expertise. Specifically, Genedata Imagence:

• rapidly detects and defines all cellular phenotypes in an HCS assay;
• efficiently generates deep learning training data for subsequent classification of HCS image sets in production assays;
• precisely quantifies the relevant pharmacology; and 
• produces quality results from a new experiment in just seconds vs. weeks typically required by manual optimization with existing legacy systems.

“Genedata Imagence is revolutionizing a key process in biopharmaceutical R&D,” said Dr. Othmar Pfannes, CEO of Genedata. “We are honored to have Bio-IT World recognize the impact of this solution for improving the efficiency of data-driven drug discovery and development. Our early-access biopharma partners are already seeing the predicted gains in efficiency and scale-up of high-content screens with Imagence. We are now rolling out Imagence to the industry to advance research in the age of artificial intelligence.”